- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05263583
Bromure de sepantronium pour le traitement du lymphome à cellules B de haut grade
Une étude de phase 2, multicentrique, ouverte sur la détermination de la dose de bromure de sepantronium chez des patients atteints de lymphome à cellules B de haut grade réarrangé c-Myc (HGBCL) récidivant/réfractaire
This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma
Aperçu de l'étude
Statut
Les conditions
- Lymphome à cellules B
- Lymphome diffus à grandes cellules B
- Maladies lymphatiques
- Lymphome de Burkitt
- Lymphome à cellules B de haut grade
- Lymphome à cellules B de haut grade à double impact C-MYC/BCL6
- Lymphome à cellules B de haut grade à double impact C-MYC/BCL2
- Lymphome de haut grade
- Réarrangement du gène C-Myc
Intervention / Traitement
Description détaillée
This is a multi-center, open label, dose-ranging Phase 2 study evaluating the safety and efficacy of SepB in patients with relapsed/refractory c-Myc rearranged HGBCL.
Cohorts of three patients will be enrolled at each dose level for SepB with expansion to six patients, if necessary, to assess toxicity.
Following the completion of 2 cycles of treatment of each cohort, an independent Data Monitoring Committee (DMC) will review the safety data to assess study drug related toxicities from the current cohort. Following this review, a decision will be made to continue dose escalation to the next dose level, to declare that a given dose level is the level of dose-limiting toxicity (DLT) or to further explore toxicity at the dose level in question by enrolling additional subjects to a maximum of six subjects at that level.
An additional 6 patients will be enrolled at the recommended Phase 2 dose (RP2D). The RP2D will be established on the basis of the maximally tolerated dose between the two specified dose levels as well as other relevant data, including clinical signals of activity, pharmacokinetic (PK) and pharmacodynamic (PD) data.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Beijing, Chine
- Beijing Cancer Hospital
-
Guangzhou, Chine
- Sun Yat-sen University Cancer Center
-
Henan, Chine
- Henan Cancer Hospital
-
Pudong, Chine
- Shanghai East Hospital
-
Tianjin, Chine
- Tianjin Cancer Hospital
-
Wuhan, Chine
- Tongji Hospital
-
-
-
-
-
Busan, Corée du Sud
- Dong-A University Hospital
-
Busan, Corée du Sud
- Inje University Haeundae Paik hospital
-
Seoul, Corée du Sud
- Samsung Medical Center
-
Seoul, Corée du Sud
- Seoul National University Hospital
-
Seoul, Corée du Sud
- Seoul St.Mary's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Confirmed histologic diagnosis of c-Myc rearranged high-grade B-cell lymphoma
- Relapse or refractory disease after at least one previous line of therapy
- Measurable disease as defined by 2014 Lugano classification
- ECOG performance status of 0-2
- Acceptable coagulation parameters
Exclusion Criteria:
- Allogeneic transplant within 3 months
- Autologous transplant without resolution of post-transplant cytopenias
- Known CNS involvement
- Average QT/QTc interval duration > 450 msec
- Inadequate marrow, hepatic or renal function
- Unresolved Grade 2 or greater toxicities from prior anticancer therapy
- Radiotherapy within prior 4 weeks
- Requires systemic immunosuppressive therapy
- Positive for Hepatis B or Hepatis C
- Seropositive for HIV
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort 1
Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide |
continuous intravenous infusion
Autres noms:
|
|
Expérimental: Cohort 2
Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide |
continuous intravenous infusion
Autres noms:
|
|
Expérimental: Recommended Phase 2 Dose - Cohort 3
The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2 |
continuous intravenous infusion
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and tolerability and recommended Phase 2 dose of sepantronium bromide
Délai: From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months
|
Frequency, severity and relatedness of adverse events and the frequency of adverse events requiring discontinuation of study drug or dose reductions |
From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall response rate
Délai: From first dose through the last dose of study drug, an average of 6 months
|
The ORR is defined as the percentage of participants who achieve either a Partial Response or Complete Response at any time during the treatment phase |
From first dose through the last dose of study drug, an average of 6 months
|
|
Complete response rate
Délai: From first dose of study drug through the last dose of study drug, an average of 6 months
|
Percentage of patients who experience a confirmed Complete Response at any time during the treatment phase |
From first dose of study drug through the last dose of study drug, an average of 6 months
|
|
Duration of response
Délai: From first dose of study drug through to time of progression, an average of 6 months
|
Time from the first documentation of a Complete Response or a Partial Response until the time to objective tumor progression |
From first dose of study drug through to time of progression, an average of 6 months
|
|
Clinical benefit rate
Délai: From first dose of study drug through the last dose of study drug, an average of 6 months
|
Proportion of patients who achieve a Complete Response, Partial Response or Stable Disease during the treatment phase |
From first dose of study drug through the last dose of study drug, an average of 6 months
|
|
Overall survival
Délai: From first dose of study drug through date of death, irrespective of cause, an average of 6 months
|
The time from the first dose of study drug until death from any cause or date of last follow-up for living and lost to follow-up patients |
From first dose of study drug through date of death, irrespective of cause, an average of 6 months
|
|
Progression Free Survival
Délai: From first dose of study drug through relapse, disease progression or death due to any cause, an average of 12 months
|
The time from first dose until relapse, disease progression or death due to any cause |
From first dose of study drug through relapse, disease progression or death due to any cause, an average of 12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Vernon Jiang, PhD, Cothera Bioscience
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Attributs de la maladie
- Maladies du système immunitaire
- Infections
- Maladies virales
- Tumeurs par type histologique
- Infections par le virus de l'ADN
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome
- Infections par le virus Epstein-Barr
- Infections à Herpesviridae
- Infections virales tumorales
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Récurrence
- Lymphome à cellules B
- Lymphome diffus à grandes cellules B
- Lymphome de Burkitt
- Lymphome non hodgkinien
- Maladies lymphatiques
- sepantronium
Autres numéros d'identification d'étude
- PC002-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
Délai de partage IPD
Beginning 9 months and ending 36 months following article publication.
Critères d'accès au partage IPD
Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .